Assertio Completes Merger with Zydus Lifesciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Merger Completion: Assertio Holdings successfully completed its merger with Zydus Lifesciences on June 16, 2026, with Assertio continuing as a wholly-owned subsidiary of Zydus, marking a significant strategic expansion for the company.
- Stock Delisting: Following the merger, Assertio's common stock has been delisted from the Nasdaq, with shareholders receiving $23.50 per share in cash, reflecting the company's valuation in the acquisition.
- Convertible Bond Changes: The merger triggers a
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 23.500
Low
35.00
Averages
40.00
High
45.00
Current: 23.500
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Assertio Completes Merger with Zydus Lifesciences
- Merger Completion: Assertio Holdings successfully completed its merger with Zydus Lifesciences on June 16, 2026, with Assertio continuing as a wholly-owned subsidiary of Zydus, marking a significant strategic expansion for the company.
- Stock Delisting: Following the merger, Assertio's common stock has been delisted from the Nasdaq, with shareholders receiving $23.50 per share in cash, reflecting the company's valuation in the acquisition.
- Convertible Bond Changes: The merger triggers a
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- SUNation Merger Investigation: Halper Sadeh LLC is investigating SUNation Energy, Inc.'s merger with Suniva, where SUNation shareholders are expected to own only about 1.8% of the combined entity, potentially impacting shareholder rights and future returns.
- Rallybio Merger Scrutiny: The merger between Rallybio Corporation and Candid Therapeutics will result in Rallybio shareholders holding approximately 3.65% of the combined company, prompting Halper Sadeh LLC to urge shareholders to understand their rights and options to protect their interests.
- Assertio Sale Review: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash, with Halper Sadeh LLC advocating for increased consideration and additional disclosures to ensure transparency and fairness in the transaction for shareholders.
- Taylor Morrison Transaction Examination: Taylor Morrison Home Corporation is being sold to Berkshire Hathaway Inc. for $72.50 per common share in cash, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and ensure equitable terms for all shareholders.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ: ASRT) for potential breaches of fiduciary duty and legal violations in its transaction with Zydus, aiming to protect shareholder rights.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competition Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, potentially harming shareholder interests and raising legal concerns.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest.
See More
FTSE Russell Microcap Index Reconstitution Begins
- Sector Rotation: FTSE Russell's preliminary list indicates that companies like Ocugen, Assertio Holdings, Senseonics, CytomX Therapeutics, and iBio are set to join the Russell Microcap Index, reflecting significant shifts within the medical and biotech sectors that could enhance these firms' market visibility and investment appeal.
- Exiting Companies: Companies such as Definium Therapeutics, Tvardi Therapeutics, Rockwell Medical, Quantum-Si, and Capricor Therapeutics are expected to leave the index, which may pressure their stock prices and affect investor confidence, particularly amid intensifying competition in the healthcare sector.
- Effective Date: The reconstitution will officially take effect after US equity markets close on June 26, meaning that the market performance of these companies will be closely monitored, and investors should position themselves ahead of potential market volatility.
- Market Reaction Anticipation: As the healthcare landscape evolves, investors may reassess the valuations of these companies, especially with new entrants likely to drive stock price increases through enhanced liquidity and market recognition.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- UniFirst Shareholder Rights Concern: UniFirst Corporation (NYSE:UNF) is being sold for $155.00 in cash and 0.7720 shares of Cintas stock per share, with Halper Sadeh LLC potentially advocating for higher transaction prices and additional disclosures to protect shareholder interests.
- Assertio Holdings Transaction Review: Assertio Holdings, Inc. (NASDAQ:ASRT) is selling to Garda Therapeutics for $18.00 per share in cash plus a contingent value right, and Halper Sadeh LLC is assessing whether this deal serves the best interests of shareholders, possibly seeking increased compensation.
- Kennedy-Wilson Transaction Risks: Kennedy-Wilson Holdings, Inc. (NYSE:KW) is being sold for $10.90 per share in cash to a consortium led by CEO William McMorrow, with Halper Sadeh LLC potentially representing shareholders to seek better terms and transparency to safeguard their investments.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Assertio Completes Merger with Zydus Lifesciences
- Merger Completion: Assertio Holdings successfully completed its merger with Zydus Lifesciences on June 16, 2026, with Assertio continuing as a wholly-owned subsidiary of Zydus, marking a significant strategic expansion for the company.
- Stock Delisting: Following the merger, Assertio's common stock has been delisted from the Nasdaq, with shareholders receiving $23.50 per share in cash, reflecting the company's valuation in the acquisition.
- Convertible Bond Changes: The merger triggers a
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- SUNation Merger Investigation: Halper Sadeh LLC is investigating SUNation Energy, Inc.'s merger with Suniva, where SUNation shareholders are expected to own only about 1.8% of the combined entity, potentially impacting shareholder rights and future returns.
- Rallybio Merger Scrutiny: The merger between Rallybio Corporation and Candid Therapeutics will result in Rallybio shareholders holding approximately 3.65% of the combined company, prompting Halper Sadeh LLC to urge shareholders to understand their rights and options to protect their interests.
- Assertio Sale Review: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash, with Halper Sadeh LLC advocating for increased consideration and additional disclosures to ensure transparency and fairness in the transaction for shareholders.
- Taylor Morrison Transaction Examination: Taylor Morrison Home Corporation is being sold to Berkshire Hathaway Inc. for $72.50 per common share in cash, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and ensure equitable terms for all shareholders.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ: ASRT) for potential breaches of fiduciary duty and legal violations in its transaction with Zydus, aiming to protect shareholder rights.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competition Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, potentially harming shareholder interests and raising legal concerns.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest.
See More
FTSE Russell Microcap Index Reconstitution Begins
- Sector Rotation: FTSE Russell's preliminary list indicates that companies like Ocugen, Assertio Holdings, Senseonics, CytomX Therapeutics, and iBio are set to join the Russell Microcap Index, reflecting significant shifts within the medical and biotech sectors that could enhance these firms' market visibility and investment appeal.
- Exiting Companies: Companies such as Definium Therapeutics, Tvardi Therapeutics, Rockwell Medical, Quantum-Si, and Capricor Therapeutics are expected to leave the index, which may pressure their stock prices and affect investor confidence, particularly amid intensifying competition in the healthcare sector.
- Effective Date: The reconstitution will officially take effect after US equity markets close on June 26, meaning that the market performance of these companies will be closely monitored, and investors should position themselves ahead of potential market volatility.
- Market Reaction Anticipation: As the healthcare landscape evolves, investors may reassess the valuations of these companies, especially with new entrants likely to drive stock price increases through enhanced liquidity and market recognition.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- UniFirst Shareholder Rights Concern: UniFirst Corporation (NYSE:UNF) is being sold for $155.00 in cash and 0.7720 shares of Cintas stock per share, with Halper Sadeh LLC potentially advocating for higher transaction prices and additional disclosures to protect shareholder interests.
- Assertio Holdings Transaction Review: Assertio Holdings, Inc. (NASDAQ:ASRT) is selling to Garda Therapeutics for $18.00 per share in cash plus a contingent value right, and Halper Sadeh LLC is assessing whether this deal serves the best interests of shareholders, possibly seeking increased compensation.
- Kennedy-Wilson Transaction Risks: Kennedy-Wilson Holdings, Inc. (NYSE:KW) is being sold for $10.90 per share in cash to a consortium led by CEO William McMorrow, with Halper Sadeh LLC potentially representing shareholders to seek better terms and transparency to safeguard their investments.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
